NCT07848399|Not Yet Recruiting
Endometrial Immune Profile in Recurrent Implantation Failure
Immunological Fingerprints of the Non-receptive Endometrium in IVF Failure: Identifying the Barriers to Pregnancy
Loading search results
Immunological Fingerprints of the Non-receptive Endometrium in IVF Failure: Identifying the Barriers to Pregnancy
Sponsor study identifier
observational
64
1 country
1
Study Start
October 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The goal of this observational study is to learn whether differences in the immune cells of the womb lining (endometrium) help explain why some women do not become pregnant despite several IVF attempts using good-quality embryos, a condition known as recurrent implantation failure (RIF). The study compares women with RIF to women who have had a natural, healthy pregnancy. The main question it aims to answer is: Do immune cells in the endometrium, including uterine natural killer cells, macrophages, B cells, and T cells, differ in number or function between women with RIF and fertile controls? Researchers will compare endometrial tissue and blood samples from the RIF group to samples from the fertile control group to see whether specific immune cell patterns are linked to implantation failure, and whether these differences could point to future treatment targets. Participants will:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 21, 2026
Actual (reported)September 30, 2026
Actual (reported)October 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Th17/Treg ratio in the endometrium
Ratio of T helper 17 (Th17) cells to regulatory T (Treg) cells in endometrial tissue, measured by flow cytometry and single-cell RNA sequencing/CITE-seq, compared between participants with recurrent implantation failure (RIF) and fertile controls.
Through study completion, up to 27 months
Reference atlas of endometrial immune cell populations
Through study completion, up to 27 months
Candidate immune targets for future therapeutic research
Through study completion, up to 27 months
Women meeting the ESHRE definition of recurrent implantation failure (failure to achieve pregnancy despite an estimated cumulative chance of implantation exceeding 60%), with unexplained infertility, recruited through King's Fertility.
Women with a history of at least one spontaneous pregnancy resulting in live birth, at least 12 months postpartum, with no history of subfertility, recruited through the Harris Birthright Centre, King's College Hospital.
Women under 40 with recurrent implantation failure following IVF, identified through clinical records at King's Fertility (Denmark Hill and Harley Street), and women with a history of spontaneous pregnancy resulting in live birth, identified through 36-week gestation scan records at the Harris Birthright Centre, King's College Hospital. Both groups are drawn from patients already attending these services, approached by their direct care team if they have previously consented to research contact.
King's Fertility
London, London, SE5 8BB, United Kingdom
Cryopreserved endometrial tissue biopsy samples, retained from all participants. Where a participant consents, an additional peripheral blood sample of up to 18ml is taken and processed to isolate cells from plasma and cryopreserved, for possible use in future ethically approved immune research.
Panicos Shangaris, MRCOG, PhD
King's College London
Ippokratis Sarris, DM, FRCOG
King's Fertility
First Submitted
September 21, 2026
First Posted
September 30, 2026
Study Start
October 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 2028
EstimatedContact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
September 30, 2026
Record last verified: 2026-09
Pseudonymised individual participant data, including transcriptomic, proteomic, and T cell receptor sequencing data, may be deposited in a controlled-access repository and/or shared directly with other researchers upon reasonable request, subject to approval by the Chief Investigator, as data custodian, and King's College London's research governance office, and a formal data sharing agreement. Given the genomic nature of the data, full anonymisation is not possible; re-identification is only possible via a secure linkage key held by designated, authorised members of the research team. Processed or summary-level data not carrying re-identification risk may be made available more openly, for example as supplementary material accompanying publications.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: